Amgen sees FY19 adjusted EPS $13.10-$14.30, consensus $14.62

Sees FY19 revenue $21.8B-$22.9B, consensus $22.94B. “Through our continued solid operating performance in 2018, we met and exceeded our long-term financial commitments. Looking to the future, we are encouraged by our long-term growth prospects driven by our portfolio of newer products, pipeline and ongoing success in international expansion,” said chairman and CEO Robert Bradway.
https://thefly.com/landingPageNews.php?id=2855417

Amicus initiated at Cantor Fitzgerald

Amicus initiated with an Overweight at Cantor Fitzgerald. Cantor analyst Elemer Piros initiated Amicus with an Overweight and $20 price target.
https://thefly.com/landingPageNews.php?id=2855431

Amgen reports Q4 Repatha sales up 62%, Neulasta up 5%

https://thefly.com/landingPageNews.php?id=2855432

Amgen reports Enbrel sales down 8% in Q4

Enbrel sales decreased 8% for the fourth quarter and the full year driven by lower unit demand and lower net selling price. NEUPOGEN sales decreased 40% for the fourth quarter driven by lower net selling price and lower unit demand. Sales decreased 34% for the full year driven by lower unit demand and lower net selling price.
https://thefly.com/landingPageNews.php?id=2855439

Amgen hit after Q4 results, FY19 guidance

In after-hours trading, Amgen shares are down $4.67, or 2.4%, to $187.44.
https://thefly.com/landingPageNews.php?id=2855447

Illumina backs FY19 adjusted EPS view $6.50-$6.60, consensus $6.46

Sees FY19 revenue growth 13%-14%, consensus $3.81B.
https://thefly.com/landingPageNews.php?id=2855451

Global Blood Therapeutics publishes sickle cell study data

Global Blood Therapeutics announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell disease were published online in Blood, a peer-reviewed publication of the American Society of Hematology. Voxelotor is being developed as a potentially disease-modifying therapy for SCD. GBT intends to submit a New Drug Application, or NDA, for voxelotor under an accelerated approval pathway to the FDA later this year. “The findings from the Phase 1/2 study and the open-label extension played an important role in our development of voxelotor. We believe voxelotor has the potential to become a standard-of-care therapy in SCD, as evidenced by its ability to reduce anemia, hemolysis and sickling,” said GBT CEO Ted Love. “Additionally, I’m pleased that we have reached agreement with the FDA on both the accelerated approval pathway for voxelotor and for transcranial doppler (TCD) flow velocity as an acceptable primary endpoint in a post-approval confirmatory study to demonstrate stroke risk reduction. We plan on initiating our TCD study later this year. I look forward to our upcoming pre-NDA meeting with the FDA for voxelotor, which will primarily focus on the format of our planned NDA filing in the second-half of this year.”
https://thefly.com/landingPageNews.php?id=2855463